412. Development of GD2-Specific Immunoliposomes for Immunotherapy of Neuroblastoma

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)34021-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Anti-Gd2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2018English

Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T Cells

Clinical Cancer Research
Cancer ResearchOncology
2009English

Development of Next Generation Antibody-Based Immunotherapy for Childhood Cancer Neuroblastoma

The Lancet
Medicine
2016English

Anti-Cd105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-Gd2 Antibody Immunotherapy of Neuroblastoma With Activated Natural Killer Cells

Clinical Cancer Research
Cancer ResearchOncology
2019English

Research and Development of Immunoliposomes

Drug Delivery System
Pharmaceutical Science
2004English

Characterization of GD2 Peptide Mimotope DNA Vaccines Effective Against Spontaneous Neuroblastoma Metastases

Cancer Research
Cancer ResearchOncology
2006English

Comparison of Pain Outcomes Between Two Anti-Gd2 Antibodies in Patients With Neuroblastoma

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2014English

Long-Term Continuous Infusion of Anti-Gd2 Antibody CH14.18/CHO in Relapsed/Refractory Neuroblastoma Patients

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

Mechanisms of Allergen-Specific Immunotherapy

Journal of Allergy and Clinical Immunology
AllergyImmunology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy